Canada markets open in 7 hours 28 minutes

LexaGene Holdings Inc. (LXG.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.8300-0.0200 (-2.35%)
At close: 3:59PM EDT
Full screen
Previous Close0.8500
Open0.8300
Bid0.8300 x 0
Ask0.8500 x 0
Day's Range0.8200 - 0.8600
52 Week Range0.4300 - 1.2800
Volume54,333
Avg. Volume292,285
Market Cap94.381M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-0.0970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • John C. Maxwell to headline BNI's 2020 Global Convention
    CNW Group

    John C. Maxwell to headline BNI's 2020 Global Convention

    Businesses seeking exceptional growth are encouraged to register early for this large-scale eventCHARLOTTE, N., Sept.

  • GlobeNewswire

    LexaGene’s CEO Provides Video Message on Company’s Progress and Announces Appointment of Dr. Shelley Rankin to Company’s Scientific Advisory Board

    BEVERLY, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to provide a video message from Dr. Jack Regan, LexaGene’s Founder and CEO, on the Company’s progress towards commercial sales and is also pleased to announce the appointment of Dr. Shelley Rankin to LexaGene’s Scientific Advisory Board. Dr. Jack Regan’s video message and MiQLab™ demonstration can be viewed on the corporate website here: https://lexagene.com/video-message-to-investors/Regarding the appointment, Dr. Regan comments, “As we approach sales, I’m very pleased to add Dr. Rankin to our Scientific Advisory Board. She is an outspoken key opinion leader in veterinary medicine and is constantly advocating for high quality diagnostics for veterinarians in order to promote better animal health and antibiotic stewardship. We look forward to working with her to help meet the needs of veterinarians worldwide.”Dr. Rankin is a Professor of Microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). She is the Chief of Clinical Microbiology and Head of Diagnostic Services at Penn Vet’s Ryan Hospital. She is a member of many scientific societies, a past Chair of the American Society for Microbiology, Animal Health Division (2011) and is currently Co-Chair of the Subcommittee on Salmonella for the United States Animal Health Association. She is an author of the International Society for Companion Animal Infectious Diseases (ISCAID) Guidelines for Antimicrobial Use to treat infections of the skin, urinary tract, and respiratory tract. She has published 100 peer reviewed papers and regularly speaks at international conferences. She has been recognized as an Association of American Veterinary Medical Colleges One Health Scholar and a Wharton Mack Institute Technology Fellow.To be added to the LexaGene email list, please subscribe on the Company website.On Behalf of the Board of Directors Dr. Jack Regan Chief Executive Officer & Director About LexaGene Holdings Inc. LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.For further information, please contact:Media Contacts Nicole Ridgedale Director of Corporate Marketing, LexaGene 800.215.1824 ext 206 nridgedale@lexagene.comInvestor Relations Jay Adelaar Vice President of Capital Markets, LexaGene 800.215.1824 ext 207 jadelaar@lexagene.comThe TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

  • GlobeNewswire

    LexaGene Engages Tailwinds Research Group

    BEVERLY, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, is pleased to announce it has engaged Tailwinds Research Group to provide digital content distribution for the Company. LexaGene engaged Tailwinds for a 1-year term, at $2,500/month USD with 100,000 stock options provided at $0.88 CAD/option.In addition, LexaGene granted a non-executive Director 350,000 options at $0.66 CAD/option to replace options priced at $0.33 CAD/option that had expired on June 27, 2020. LexaGene also granted a second non-executive Director 170,000 restricted share units (RSUs) to replace an equal number of RSUs that expired on September 12, 2020.To be added to the LexaGene email list, please subscribe on the Company website.On Behalf of the Board of Directors Dr. Jack Regan Chief Executive Officer & Director About LexaGene Holdings Inc. LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’. The MiQLab™ system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.For further information, please contact:Media Contacts Nicole Ridgedale Director of Corporate Marketing, LexaGene 800.215.1824 ext 206 nridgedale@lexagene.comInvestor Relations Jay Adelaar Vice President of Capital Markets, LexaGene 800.215.1824 ext 207 jadelaar@lexagene.comThe TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.